

Sensitivity and specificity values of high-risk HPV DNA, p16/ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL)

A. FREGA¹, M. PAVONE¹, F. SESTI², C. LEONE¹, P. BIANCHI¹, G. COZZA¹, C. COLOMBRINO¹, A. LUKIC¹, R. MARZIANI¹, L. DE SANCTIS³, G. DELLI CARPINI⁴, D. CASERTA¹, A. CIAVATTINI⁴

¹Department of Surgery, Medicine and Translational Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy

²Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

³Obstetrical and Gynecological Unit, "Valli del Noce" Hospital, Cles, Trento, Italy

⁴Woman's Health Sciences Department, Gynecologic Section, Polytechnic University of Marche, Ancona, Italy

Abstract. – OBJECTIVE: The aim of the study was to evaluate the sensitivity and specificity values of high-risk HPV DNA test, p16/ki-67, and HPV mRNA in histologically high-grade cervical intraepithelial lesions (CIN2-CIN3) in women aged 21-24 years with diagnosis of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) at pap smear.

PATIENTS AND METHODS: 342 patients between 21-24 years old, attending spontaneously our clinics, 118 with ASCUS and 224 with LSIL, were enrolled in the study. All patients underwent colposcopy and biopsies were performed in the areas with major changes. All patients were tested at the same time for p16/ki-67, high-risk HPV DNA and HPV mRNA.

RESULTS: Nineteen out of 118 women with ASCUS showed a high-grade cervical intraepithelial lesion, 11 out of 118 (9.32%) CIN2, and 8 out of 118 (6.78%) CIN3. The sensitivity of high-risk HPV DNA was 99.9%, and the specificity 23.2%; p16/ki-67 pointed out a sensitivity of 90.9%, and a specificity of 81.8%; HPV mRNA showed a sensitivity of 81.8%, and specificity of 87.9% in CIN2 lesions. In CIN3 lesions, the sensitivity of high-risk HPV DNA was 99.9%, while the specificity was 19.1%; p16/ki-67 showed a sensitivity of 99.9%, and a specificity of 73.7%; HPV mRNA relived a sensitivity of 87.5%, and a specificity of 80.8%. In women with LSIL, a total of 42/224 (18.75%) of CIN2 were found at the histopathological examination, while 17/224 (7.59%) women presented a CIN3. No case of invasive cancer was identified. High-risk HPV DNA was positive

in 190/224 (84.8%), p16/ki-67 in 119/224 (53.1%), and HPV mRNA in 104/224 (46.4%). In women with CIN2, the sensitivity of high-risk HPV DNA was of 92.8%, and the specificity 17.5%, the sensitivity of p16/ki-67 was 95.2%, and specificity 61.8%. HPV mRNA showed a sensitivity of 88.8% and a specificity of 87.8%. In women with CIN3, the sensitivity of high-risk HPV DNA was 88.2%, and the specificity 29.7%; p16/ki-67 pointed out a sensitivity of 94.1%, and a specificity of 49%; HPV mRNA showed a sensitivity of 88.2% and a specificity of 80.6.

CONCLUSIONS: Taking into account the high rate of spontaneous regression of high-grade lesions in young women, these tests, in particular, the HPV mRNA test, used as a triage test for ASCUS or LSIL, can modify follow-up triage strategy. In fact, this biomarker, due to its high specificity, could lead to a cytology repetition instead of an immediate colposcopy, avoiding over diagnosis and potential overtreatment in this category of women.

Key Words:

Young women, Human papilloma virus, Low-grade squamous intra-epithelial lesions, Atypical squamous cells of undetermined significance, High-risk HPV DNA test, HPV mRNA test, p16/Ki-67, Colposcopy.

Introduction

It is well known how HPV infection is the most common sexual transmitted infection worldwide

with a prevalence of 30% in women younger than 25 years old. Different studies from several research groups have demonstrated the same trend with a peak of infection in girls under 25 years old and an abiding wane hereafter. This virus appears quickly afterwards the first sexual activity and more than 50% of young women has a positive HPV test in 3-4 years from the exposition¹. The reason for this remarkable prevalence is due to their sexual behavior and/or immunological vulnerability. The risk for adolescents to be infected more than adult women can be also find in the number of sexual partners or in the wrong use of the condom. Moreover, in adolescent's cervix the area of columnar and metaplastic epithelium is more represented than in the adult's one. All these reasons contribute to the higher risk of HPV infection in this age, in addition to the physiological immune immaturity². There is strong evidence in the literature that persistent high-risk HPV infection is a necessary cause for the development of high-grade cervical intraepithelial lesion (CIN2-3), which could progress to invasive cervical carcinoma in an estimated period of 10-20 years³. The prevention of cervical carcinoma is strongly based on the use of HPV vaccination, and the early diagnosis of pre-neoplastic lesions made by cervical cytology and colposcopy. In the last decades, the great improvement in prevention strategies has brought to a reduction of mortality but not to a decrease of the incidence for this neoplasia^{4,5}, even in young patients. Indeed, in Europe and America there were 38,704 new cases of cervical cancer among women 15-39 years old, and the UK Cancer Research has collected 450 new cases of cervical cancer in the United Kingdom in 2014 among women between 25 and 29 years old⁴. Actually, the management of cervical pre-neoplastic lesions in young patients is as much conservative as possible, considering the reported high rate of regression in this period of life, and the increased risk of prematurity, neonatal mortality, and morbidity in subsequent pregnancies after cervical excisional treatments^{6,7}. More specifically, CIN1 lesions do not need any kind of treatment, CIN2 lesions require observation, and CIN3 lesions require an immediate intervention⁸, since they present a significantly lower regression rate⁹. Therefore, it becomes of crucial importance to identify correct strategies to carefully select women that may develop histologically advanced lesions, in order to reduce the gap between the cytological finding of a dubious lesion and the execution of a biopsy under colposcopy guidance,

decreasing the risk of unnecessary treatments. It is well known the better efficacy to predict HSIL using more specific molecular tests, like HPV mRNA test and p16/ki-67 respect on HR HPV DNA in adult population taking part in the screening programs¹⁰.

The aim of the study was to evaluate the performance of high-risk HPV DNA test, p16/ki-67 (Dual stain test) and HPV mRNA test in histologically high-grade lesions (CIN2-CIN3) in women aged 21-24 years with diagnosis of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) at pap smear.

Patients and Methods

An observational cohort study was conducted between January 2009 and September 2017 on women aged 21-24 years old, who attended spontaneously to our clinics, with cytological diagnosis of atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL). All women underwent colposcopy and were tested at the same time for p16/ki-67 dual stain cytology (Cintec PLUS Cytology kit; Roche laboratories, Mannheim, Germany), HC2 HPV test (Digene HC2 HPV DNA Test, Digene Corporation, Gaithersburg, MA, USA), and HPV mRNA Test (PreTect HPV Proofer Kit NorChip, Klokkarstua, Norway). The exclusion criteria were: oral contraceptive treatment longer than 5 years, previous ablative or excisional cervical treatments, systemic disease (e.g., metabolic disorders, immunodepression, infections), pregnancy, smoke, alcohol or substance abuse.

The cytological findings were classified according to Bethesda system terminology (Bethesda, 2001). The colposcopy was performed by Zeiss Colposcope T 50 (Carl Zeiss, Inc., Jena, Germany). The colposcopy findings were reported according to the International Federation for Cervical Pathology and Colposcopy (IFCPC) 2011 colposcopic terminology. The colposcopies performed before the introduction of the 2011 IFCPC nomenclature were revised accordingly through the revision of colposcopic finding. Colposcopy was considered satisfactory if the squamous-columnar junction (SCJ) was entirely identified. All biopsies were performed under colposcopy guidance in the areas with major changes. The histopathological findings were classified as

negative, cervical intraepithelial neoplasia grade 1 (CIN1), cervical intraepithelial neoplasia grade 2 (CIN2), cervical intraepithelial neoplasia grade 3 (CIN3), or suspicious for invasive cancer.

The values of sensitivity and specificity in detection of CIN2 or CIN3 lesions for p16/ki-67 dual stain cytology, HC2 HPV test, and HPV mRNA test were performed according to the referral cervical cytology results (ASCUS or LSIL).

A written informed consent was obtained by all the included women. The study was reviewed and approved by the Institutional Review Board.

Statistical sample size considerations were based on estimation of the sensitivity and specificity with widths of 95% confidence intervals (95% CIs). The diagnostic performance results are reported without correction for verification bias.

Results

Women with ASCUS Cervical Cytology

19 out of 118 women with ASCUS presented a high-grade cervical intraepithelial lesion at colposcopy directed biopsy, 11 out of 118 (9.32%) women presented a CIN2, and 8 out of 118 (6.78%) a CIN3. No case of invasive cancer was found. High-risk HPV DNA test was positive in 96/118 (83.9%) women, p16/ki-67 in 62 /118 (52.5%), and HPV mRNA test in 47/118 (40.3%). In women with a diagnosis of CIN2, the sensitivity of high-risk HPV DNA was 99.9%, and the specificity 23.2%; p16/ki-67 pointed out a sensitivity of 90.9% and a specificity of 81.8%; HPV mRNA showed a sensitivity of 81.8% and specificity of 87.9%.

In women with a diagnosis of CIN3, the sensitivity of high-risk HPV DNA was 99.9%, while the specificity was 19.1%; p16/ki-67 showed a sensitivity of 99.9% and a specificity of 73.7%; HPV mRNA showed a sensitivity of 87.5%, and a specificity of 80.8% (Table I).

Women with LSIL Cervical Cytology

In women with LSIL, a total of 42/224 (18.75%) of CIN2 were found at the histopathological examination, while 17/224 (7.59%) women presented a CIN3. No case of invasive cancer was identified. High-risk HPV DNA was positive in 190/224 (84.8%), p16/ki-67 in 119/224 (53.1%) and HPV mRNA in 104/224 (46.4%). In women with CIN2, the sensitivity of high-risk HPV DNA was of 92.8%, and the specificity 17.5%,

the sensitivity of p16/ki-67 was 95.2% and specificity 61.8%. HPV mRNA showed a sensitivity of 88.8%, and a specificity of 87.8%. In women with CIN3, the sensitivity of high-risk HPV DNA was 88.2%, and the specificity 29.7%; p16/ki-67 pointed out a sensitivity of 94.1%, and a specificity of 49%; HPV mRNA showed a sensitivity of 88.2% and a specificity of 80.6 (Table II).

Discussion

Literature databases^{11,12} are plenty of information regarding how to triage ASCUS or LSIL lesions in women older than 30 years. One of the most important innovation was the co-test based on Pap test and high-risk HPV DNA test in women with suspicious lesions. However, this protocol is not applicable to patients under the age of 30 due to an excessive rate of exposure for high-risk HPV strains that compromise the specificity of the examination¹³. According to the guidelines, the finding of ASCUS or LSIL lesions in young women between 21 and 24 years old requires cytology repetition after 12 months. If the lesion of the second cytology check is lower than ASC-H or HSIL, a second pap test is performed after further 12 months; if greater or equal to ASC-H or HSIL the patient is sent to colposcopy. Colposcopy and cytological control will continue for 2 years with a six-month interval for ASC-H or HSIL lesions. If these lesions persist for 12 months, biopsy is recommended; if HSIL persist for 24 months excision is recommended; if they are negative in two controls, patients can return to routine screening¹⁴. It is important to emphasize how during this period the patient is subjected to numerous checks with high costs in terms of resources and psychological stress.

We have turned our attention to girls between 21-24 years for whom the guidelines are currently very restrictive regarding the treatment. Our research has taken in consideration the possibility of using different markers to identify histologically advanced lesions in young patients and was conducted on 342 patients between 21-24 years old diagnosed with ASCUS or LSIL. It allowed us to highlight and compare the specificity and sensitivity values of lesion markers that could help in the early diagnosis of cytologically low-grade and histologically CIN2-3 lesions. Our study showed a prevalence of high-grade histological lesions similar to what is reported in the scientific literature¹⁵. Co-testing with high-

Table I. Sensitivity and specificity of p16/ki-67, HR HPV DNA, and HPV mRNA in women with ASCUS.

	CIN 2						CIN 3					
	N. positive results		Sensitivity		CI 95%	Specificity	CI 95%	N. positive results		Sensitivity	CI 95%	Specificity
p16/ki-67	62/118	52.5%	10/11	90.09%	(89.4-92.4%)	81.8%	(74.2-89.4%)	8/8	99.9%	(92.2-99.9%)	73.7%	(65.0-82.4%)
HR HPV DNA	96/118	83.9%	11/11	99.9%	(93.1-99.9%)	23.2%	(14.9-31.5%)	8/8	99.9%	(92.2-99.9%)	19.1%	(8.2-30.0%)
HPV mRNA	47/118	40.3%	9/11	81.8%	(59.0-99.9%)	87.9%	(81.5-94.3%)	7/8	87.5%	(64.6-99.9%)	80.8%	(73.1-88.5%)

N. of women with ASCUS: 118 (11 CIN 2 (9.32%) 8 CIN3 (6.78%)).

Table II. Sensitivity and specificity of p16/ki-67, HR HPV DNA and HPV mRNA in women with LSIL.

	CIN 2						CIN 3					
	N. positive results		Sensitivity		CI 95%	Specificity	CI 95%	N. positive results		Sensitivity	CI 95%	Specificity
p16/ki-67	119/224	53.1%	40/42	95.2%	(88.7-99.9%)	61.8%	(54.4-69.2%)	16/17	94.1%	(82.9-99.9%)	49%	(41.4-56.6%)
HR HPV DNA	190/224	84.8%	39/42	92.8%	(85.0-99.9%)	17.5%	(2.2-32.8%)	15/17	88.2%	(72.9-99.9%)	29.7%	(22.7-36.7%)
HPV mRNA	104/224	46.4%	37/42	88.8%	(79.3-98.3%)	87.8%	(82.5-93.1%)	15/17	88.2%	(72.9-99.9%)	80.6%	(73.9-87.9%)

N. of women with LSIL: 224 (42 CIN 2 (18.75%) 17 CIN3 (7.59%)).

risk HPV DNA test and Pap test in triage of both ASCUS and LSIL lesions seems to not be useful for diagnostic purposes in this age group. Although the sensitivity of high-risk HPV DNA test is extremely high (99.9% for ASCUS and 93% for LSIL), the specificity is too low to be useful for diagnosis (23% for ASCUS and 17% for LSIL).

The role of the evaluation of the p16/ki-67 is different. The overexpression of this marker is extremely useful in the framing of lesions. The specificity of the tests based on the research of the p16 is considerably higher than that offered by the HPV test, especially under 25 years, due to the enormous spread of the virus among young women. It is known that the co-expression of p16 and Ki-67 in the same cell is strongly associated with established high-grade disease. In spite of that, the dual stained cytology showed 95.1% of sensitivity, and 72.4% specificity values for histologically CIN lesions after an ASCUS cervical cytology, and 96.7% and 62.1% from a LSIL cervical cytology¹⁶. The increase of p16 expression is directly related to the interruption of the negative feedback mediated by the Rb protein. Alterations of these physiological mechanisms are implications of the integration of the viral genome into the host cell¹⁷; the increase in Ki-67 levels is also a sign of de-regulation of the cell cycle. Looking for an ideal high-grade lesion marker, the study of the expression of the E6 and E7 oncoproteins mRNA may play an important role¹⁸. In fact, the expression of E6 and E7 proteins is ubiquitous in all cases of cervical cancer. This is decisive for the high specificity that this marker assumes^{19,20}. Furthermore, all studies^{21,22} conducted over the years have shown that once viral DNA has been integrated and the oncoproteins have been expressed, the biological behavior will no longer depend on the genotype.

Conclusions

These data revealed the importance of the mRNA test to define how severe is a lesion. The specificity of the HPV mRNA test in defining CIN2 lesions in women with ASCUS was 88.0%. It is much higher than what the HPV test has shown for 23% and higher than what the p16/ki-67 did for 72.4%. The same evidence was found in patients with LSIL, where the specificity of the test was 88.0%, respect to 62.1% for the p16/ki-67 and 17% for the HPV test. It was shown that the

specificity of high-risk HPV DNA test is too low in women aged 21-24 years²³. For this reason, this test cannot be used in the triage of patients with ASCUS or LSIL in this age group. On the contrary, between 21-24 years the HPV mRNA test and even more, the p167/ki-67 have demonstrated specificity and sensitivity values that seem to be optimal for the early detection of histologically high-grade cervical intraepithelial lesions. The introduction of these tests for the follow-up of young women with ASCUS and LSIL could lead to improve the management of these lesions in young women. Taking into account the high rate of spontaneous regression of high-grade lesions in young women, these tests, in particular the HPV mRNA test, used as a triage test for ASCUS or LSIL, can modify follow-up triage strategy. In fact, this biomarker, due to the high specificity values, could lead to a cytology repetition instead of an immediate colposcopy, avoiding over diagnosis and potential overtreatment in this category of patients.

Conflict of Interest

The Authors declare that they have no conflict of interests.

References

- 1) MOSCICKI AB. Management of adolescents with abnormal cytology and histology. *Obstet Gynecol Clin North Am* 2008; 35: 633-643.
- 2) MOSCICKI AB, COX JT. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. *J Low Genit Tract Dis* 2010; 14: 73-80.
- 3) SOPRACORDEVOLE F, BARBERO M, CLEMENTE N, FALLANI MG, CATTANI P, AGAROSI A, DE PIERO G, PARIN A, FREGA A, BOSELLI A, MANCIOLI F, BUTTIGNOL M, CURRADO F, PIERALLI A, CIAVATTINI A; ITALIAN SOCIETY OF COLPOSCOPY AND CERVICO-VAGINAL PATHOLOGY (SICPCV). High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). *Eur Rev Med Pharmacol Sci* 2016; 20: 818-824.
- 4) FERLAY J, SOERJOMATARAM I, DIKSHIT R, ESER S, MATHERS C, REBELO M, PARKIN DM, FORMAN D, BRAY F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: 359-386.
- 5) LANDY R, PESOLA F, CASTAÑÓN A, SASIENI P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. *Br J Cancer* 2016; 115: 1140-1146.

- 6) KYRGIU M, ATHANASIOU A, KALLIALA IEJ, PARASKEVAIDI M, MITRA A, MARTIN-HIRSCH PP, ARBYN M, BENNETT P, PARASKEVAIDIS E. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. *Cochrane Database Syst Rev* 2017; 11: CD012847.
- 7) LIVERANI CA, DI GIUSEPPE J, CLEMENTE N, DELLI CARPINI G, MONTI E, FANETTI F, BOLIS G, CIAVATTINI A. Length but not transverse diameter of the excision specimen for high-grade cervical intraepithelial neoplasia (CIN 2-3) is a predictor of pregnancy outcome. *Eur J Cancer Prev* 2016; 25: 416-422.
- 8) MASSAD LS, EINSTEIN MH, HUH WK, KATKI HA, KINNEY WK, SCHIFFMAN M, SOLOMON D, WENTZENSEN N, Lawson HW; 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. *J Low Genit Tract Dis* 2013; 17 (5 Suppl 1): S1-S27.
- 9) MOTAMEDI M, BÖHMER G, NEUMANN HH, VON WASIELEWSKI R. CIN III lesions and regression: retrospective analysis of 635 cases. *BMC Infect Dis* 2015; 15: 541.
- 10) WHITE C, BAKHIET S, BATES M, KEEGAN H, PILKINGTON L, RUTTLE C, SHARP L, O' TOOLE S, FITZPATRICK M, FLANNELLY G, O' LEARY JJ, MARTIN CM. Triage of LSIL/ASCUS with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study. *Cytopathology* 2016; 27: 269-276.
- 11) PEETERS E, WENTZENSEN N, BERGERON C, ARBYN M. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. *Cancer Cytopathol* 2019; 127: 169-180.
- 12) VERDOODT F, SZAREWSKI A, HALFON P, CUSCHIERI K, ARBYN M. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. *Cancer Cytopathol* 2013; 121: 675-687.
- 13) VEIJALAINEN O, TUOMISAARI S, LUUKKAALA T, MÄENPÄÄ J. High risk HPV testing in the triage of repeat ASCUS and LSIL. *Acta Obstet Gynecol Scand* 2015; 94: 931-936.
- 14) SASLOW D, SOLOMON D, LAWSON HW, KILLACKEY M, KULASINGAM SL, CAIN J, GARCIA FA, MORIARTY AT, WAXMAN AG, WILBUR DC, WENTZENSEN N, DOWNS LS JR, SPITZER M, MOSCICKI AB, FRANCO EL, STOLER MH, SCHIFFMAN M, CASTLE PE, MYERS ER; ACS-ASCCP-ASCP CERVICAL CANCER GUIDELINE COMMITTEE. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA Cancer J Clin* 2012; 62: 147-172.
- 15) DE MARCO DEMARCO M, LOREY TS, FETTERMAN B, CHEUNG LC, GUIDO RS, WENTZENSEN N, KINNEY WK, POITRAS NE, BEFANO B, CASTLE PE, SCHIFFMAN M. Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the foundation of risk-based cervical screening guidelines. *J Low Genit Tract Dis* 2017; 21: 261-267.
- 16) BERGERON C, IKENBERG H, SIDERI M, DENTON K, BOGERS J, SCHMIDT D, ALAMEDA F, KELLER T, REHM S, RIDDER R; PALMS STUDY GROUP. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. *Cancer Cytopathol* 2015; 23: 373-381.
- 17) SCHMIDT D, BERGERON C, DENTON KJ, RIDDER R; EUROPEAN CINTEC CYTOLOGY STUDY GROUP. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology. *Cancer Cytopathol* 2011; 119: 158-166.
- 18) FREGA A, SESTI F, LOMBARDI D, VOTANO S, SOPRACORDEVOLE F, CATALANO A, MILAZZO GN, LOMBARDO R, AS-SORGI C, OLIVOLA S, CHIUSURI V, RICCIARDI E, FRENCH D, MOSCARINI M. Assessment of HPV-mRNA test to predict recurrent disease in patients previously treated for CIN 2/3. *J Clin Virol* 2014; 60: 39-43.
- 19) PIERRY D, WEISS G, LACK B, CHEN V, FUSCO J. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than papanicolaou screening for women regardless of age. *Archi Pathol Lab Med* 2012; 136: 956-960.
- 20) FRENCH D, BELLEUDI F, MAURO MV, MAZZETTA F, RAFFA S, FABIANO V, FREGA A, TORRISI MR. Expression of HPV16 E5 down-modulates the TGFbeta signaling pathway. *Mol Cancer* 2013; 12: 38.
- 21) SOTLAR K, STUBNER A, DIEMER D, MENTON S, MENTON M, DIETZ K, WALLWIENER D, KANDOLF R, BÜLTMANN B. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. *J Med Virol* 2004; 74: 107-116.
- 22) NAKAGAWA S, YOSHIKAWA H, YASUGI T. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. *J Med Virol* 2000; 62: 251-258.
- 23) RONCO G, GIORGI-ROSSI P, CAROZZI F, CONFORTINI M, DALLA PALMA P, DEL MISTRO A, GHIRINGHELLO B, GIRLANDO S, GILLIO-TOS A, DE MARCO L, NALDONI C, PIEROTTI P, RIZZOLO R, SCHINCAGLIA P, ZORZI M, ZAPPA M, SEGNIAN N, CUZICK J; NEW TECHNOLOGIES FOR CERVICAL CANCER SCREENING (NTCC). Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. *Lancet Oncol* 2010; 11: 249-257.